KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) EBIT Margin (2018 - 2025)

Historic EBIT Margin for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to 3.09%.

  • BioNTech SE's EBIT Margin fell 39300.0% to 3.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.0%, marking a year-over-year increase of 17100.0%. This contributed to the annual value of 47.77% for FY2024, which is 658500.0% down from last year.
  • Latest data reveals that BioNTech SE reported EBIT Margin of 3.09% as of Q3 2025, which was down 39300.0% from 192.14% recorded in Q2 2025.
  • BioNTech SE's EBIT Margin's 5-year high stood at 84.95% during Q4 2021, with a 5-year trough of 750.74% in Q2 2024.
  • For the 5-year period, BioNTech SE's EBIT Margin averaged around 59.14%, with its median value being 35.58% (2023).
  • Per our database at Business Quant, BioNTech SE's EBIT Margin tumbled by -4148400bps in 2024 and then skyrocketed by 5586000bps in 2025.
  • BioNTech SE's EBIT Margin (Quarter) stood at 84.95% in 2021, then dropped by -9bps to 76.97% in 2022, then plummeted by -54bps to 35.58% in 2023, then tumbled by -65bps to 12.49% in 2024, then crashed by -125bps to 3.09% in 2025.
  • Its last three reported values are 3.09% in Q3 2025, 192.14% for Q2 2025, and 292.18% during Q1 2025.